Search

Displaying results 8781 - 8790 of 10000 in total
  1. Drug

    Human umbilical cord blood mononuclear cell-conditioned medium

    go.drugbank.com/drugs/DB15724
    Experimental

    Thus, the media in which they are cultured is believed to also have therapeutic potential. … Transplantation with human umbilical cord blood mononuclear cells (HUCBC) has demonstrated promising results in various disease states.

  2. Drug

    LuLym-T

    go.drugbank.com/drugs/DB17405
    Experimental

    LuLym-T is an investigational autologous immune cell therapy consisting of activated T Lymphocytes. Developed by Lukas Biomedical, Inc., it is currently being investigated in hepatocellular carcinoma.

  3. Drug

    Formebolone

    go.drugbank.com/drugs/DB01569
    IllicitInvestigational

    Formebolone, a derivative of androstane, is an anabolic androgenic steroid. It is on the list of substances prohibited by the Word Anti-Doping Agency, and is regularly screened for in athletes. … [A14416] It is also classified by the US Drug Enforcement Administration as Schedule III drug in the Controlled Substances Act.

  4. Drug

    Etidocaine

    go.drugbank.com/drugs/DB08987
    Approved

    Etidocaine is marketed under the name Duranest. It is an injectable local anesthetic during surgery, labor, and delivery. … Etidocaine has a long duration of activity, but has the main disadvantage of increased bleeding during oral surgery.

  5. Drug

    Arbekacin

    go.drugbank.com/drugs/DB06696
    Investigational

    An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant _Staphylococcus aureus_ (MRSA).

    Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index
  6. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. … Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System

  7. Drug

    Chlormadinone acetate

    go.drugbank.com/drugs/DB15903
    ApprovedWithdrawn

    Chlormadinone acetate is a progesterone derivative first synthesized in 1961. … In the US, chlormadinone acetate was formerly marketed as a component of the combination drug products Estalor-21 and C-Quens.

  8. Drug

    IPH 1101

    go.drugbank.com/drugs/DB05754
    Experimental

    IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset. … IPH 1101 is the most advanced drug candidate of the γδ T cell platform

  9. Drug

    Amolimogene bepiplasmid

    go.drugbank.com/drugs/DB04904
    Investigational

    Amolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV). … Amolimogene was biologically engineered as a targeted therapy for the treatment of cervical dysplasia.

  10. Drug

    Butropium

    go.drugbank.com/drugs/DB15968
    Experimental